James Andrew  Pierce net worth and biography

James Pierce Biography and Net Worth

Insider of Stryker

Andy Pierce became Group President, MedSurg and Neurotechnology in August 2019.

Andy oversees our Endoscopy, Instruments, Medical, Neurovascular and Craniomaxillofacial (CMF) Divisions, our Asia Pacific Region, Customer Solutions and Flex Financial Businesses, and Enterprise Strategy Function. He joined Stryker in 1996 and has held various marketing, sales and product management roles in our Instruments and CMF Divisions, later moving into leadership positions within the CMF Business. In 2008, Andy became the Vice President and General Manager of CMF, in 2009 Vice President and General Manager for our Surgical and Neuro Spine ENT Business Units and in 2013, President of our Endoscopy Division. Andy served as Group President, MedSurg in 2018 and assumed responsibility for the Neurotechnology Group in 2019. In 2021, he assumed responsibility for the Asia Pacific Region and Enterprise Strategy Function.

Andy graduated from Hope College, where he earned a bachelor's degree in business, psychology and political science.

What is James Andrew Pierce's net worth?

The estimated net worth of James Andrew Pierce is at least $18.08 million as of February 2nd, 2023. Mr. Pierce owns 46,676 shares of Stryker stock worth more than $18,080,882 as of December 3rd. This net worth estimate does not reflect any other investments that Mr. Pierce may own. Learn More about James Andrew Pierce's net worth.

How do I contact James Andrew Pierce?

The corporate mailing address for Mr. Pierce and other Stryker executives is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. Stryker can also be reached via phone at (269) 385-2600 and via email at [email protected]. Learn More on James Andrew Pierce's contact information.

Has James Andrew Pierce been buying or selling shares of Stryker?

James Andrew Pierce has not been actively trading shares of Stryker during the last quarter. Most recently, James Andrew Pierce sold 400 shares of the business's stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $277.88, for a transaction totalling $111,152.00. Following the completion of the sale, the insider now directly owns 46,676 shares of the company's stock, valued at $12,970,326.88. Learn More on James Andrew Pierce's trading history.

Who are Stryker's active insiders?

Stryker's insider roster includes Yin Becker (VP), William Berry, Jr. (VP), Glenn Boehnlein (CFO), Srikant Datar (Director), Roch Doliveux (Director), M. Fink (VP), Robert Fletcher (VP), Allan Golston (Director), Kevin Lobo (Chair and CEO), Katherine Owen (VP), James Pierce (Insider), Bijoy Sagar (VP), Timothy Scannell (COO), and Ronda Stryker (Director). Learn More on Stryker's active insiders.

Are insiders buying or selling shares of Stryker?

In the last year, insiders at the medical technology company sold shares 9 times. They sold a total of 489,490 shares worth more than $165,788,442.76. The most recent insider tranaction occured on November, 7th when CEO Kevin Lobo sold 57,313 shares worth more than $21,131,303.10. Insiders at Stryker own 5.5% of the company. Learn More about insider trades at Stryker.

Information on this page was last updated on 11/7/2024.

James Andrew Pierce Insider Trading History at Stryker

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2023Sell400$277.88$111,152.0046,676View SEC Filing Icon  
See Full Table

James Andrew Pierce Buying and Selling Activity at Stryker

This chart shows James Andrew Pierce's buying and selling at Stryker by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Stryker Company Overview

Stryker logo
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Read More

Today's Range

Now: $387.37
Low: $386.46
High: $389.68

50 Day Range

MA: $368.51
Low: $345.14
High: $392.15

2 Week Range

Now: $387.37
Low: $285.79
High: $398.20

Volume

330,886 shs

Average Volume

1,263,798 shs

Market Capitalization

$147.67 billion

P/E Ratio

41.52

Dividend Yield

0.82%

Beta

0.94